Affimed is a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer. Affimed’s fit-for-purpose ROCK® platform allows innate immune engagers to be designed for specific patient populations. The Company is developing single and combination therapies to treat cancers. A number of clinical and preclinical programs are in development based on the ROCK® platform and Affimed’s tetravalent bispecific immune cell engagers have already shown a favorable safety profile and promising signs of therapeutic efficacy.